Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
OLMA 01.02.2025
Drug:OP-1250 palazestrant
Diseases:breast cancer
Date of Upcoming Event:2025-01-14
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) --Olema Pharmaceuticals, Inc.(“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14, 2025 at 3:45 p.m. PT (6:45 p.m. ET).
A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema’s Investor Relations website atir.olema.com. A recording of the presentation will be made available in the same location.
About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us atwww.olema.com.
Media and Investor Relations ContactCourtney O’KonekVice President, Corporate CommunicationsOlema Oncologymedia@olema.com
